In the subgroup of non-squamous with unknown EGFR and ALK status, the comparison between ICI and chemotherapy showed no significant difference in the risk of CIP for all grades and grades 3–5 (OR = 0.67, 95% CI 0.35–1.29, p = 0.23; OR = 0.65, 95% CI 0.29–1.50, p = 0.32). This evidence concerns the gene ALK and hereditary sensory and autonomic neuropathy.